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Abstract
Background: Achieving control of hypertension prevents target organ damage at both the micro
and macrovascular level and is a highly cost effective means of lowering the risk for heart attack
and stroke particularly in people with diabetes. Clinical trials demonstrate that blood pressure
control can be achieved in a large proportion of people. Translating this knowledge into widespread
practice is the focus of the Hypertension Management Initiative, which began in 2004 with the goal
of improving the management of this chronic health condition by primary care providers and
patients in the community.
Methods: This study will test the effect of a systems change on the management of high blood
pressure in real world practice in primary care in Ontario, Canada. The systems change
intervention involves an interprofessional educational program bringing together physicians, nurses
and pharmacists with tools for both providers and patients to facilitate blood pressure
management. Each of two waves of subjects were enrolled over a 6 month period with the initial
enrollment between waves separated by 9 months. Blood pressure will be measured with the
BpTru ® automated blood pressure device. To determine the effectiveness of the intervention, a
before and after analysis within all subjects will compare blood pressure at baseline to annual
measurements for the three year study. To assess whether the intervention has an impact on blood
pressure control independent of community trends, a betwen group comparison of baseline blood
pressures in the delayed wave will be made with the immediate wave during the same time period,
so that the immediate wave has experienced the intervention for at least 9 months. The total
enrollment goal is 5,000 subjects. The practice locations include 10 Family Health Teams (FHTs)
and 1 Community Health Centre (CHC) and approximately 49 primary care physicians, 15 nurse
practitioners, 37 registered nurses and over 150 community pharmacists across the 11
communities throughout the province of Ontario. The 11 primary care sites will be divided into
immediate and delayed groups based on geography and the use of an electronic versus a traditional
chart patient record.
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Discussion: Initial consideration was given to randomizing the groups, however, for a number of
reasons, this was deemed to not be possible. In order to ensure that the sites in the immediate
intervention and delayed intervention groups are not different from each other, the sites will be
assigned to the intervention groups manually to ensure a distribution of the variables as evenly as
possible.
Given that HSFO approached this particular group of health care providers to participate in a
program relating to hypertension, this may have heightened their awareness of the issue and
affected their management of patients with hypertension. Thus, data will be collected to allow an
assessment of previous practice patterns and determine any impact of the Hawthorne Effect.
Trial registration: Clinicaltrials.gov NCT00425828
Background
Hypertension: Its Burden of Disease
Hypertension is a major risk factor for cardiovascular
morbidity and mortality, which in Canada, is the diagnos-
tic category ranked as the highest for drug expendi-
tures[1]. The economic burden of chronic disease in
Ontario accounts for 55% of direct and indirect total
health costs in Canada [1]. With the current demographic
changes in the province of Ontario due to the aging of the
'Baby Boomer' generation, an unusually large cohort born
between 1946 and 1965, provincial health plans are grap-
pling with how to plan for the 'silver tsunami' as this gen-
eration become senior citizens over the next 23 years.
Hypertension, also referred to as the 'silent killer', is a sig-
nificant chronic health condition, and is prevalent in over
1 out of 5 adult Canadians [2]. Despite being the number
one diagnosis listed for patient visits, a substantial pro-
portion of people remain unaware of their hypertension
or have not achieved treatment targets [3]. Data compiled
by the Heart and Stroke Foundation of Ontario indicate
that consumers do not take hypertension seriously, that
physicians are not consistently applying clinical practice
guidelines related to diagnosis and treatment targets, that
patients are not adhering to prevention and treatment rec-
ommendations and that physicians lack time and skill to
counsel patients about needed lifestyle modifications.
Clinical trials demonstrate the efficacy and safety of blood
pressure control and clinical practice recommendations
provide guidance to achieve blood pressure targets [4].
However, to achieve the benefits from blood pressure con-
trol across the entire population, without expending an
ever larger fraction of primary care physician's time to the
management of this chronic disease, a new paradigm is
required. The goal of the Heart and Stroke Foundation of
Ontario's Hypertension Management Initiative is a sus-
tainable chronic disease management model for blood
pressure control, to economically realize the public health
benefits of achieving blood pressure targets and the
attendant reduction of heart attack and stroke.
The High Blood Pressure AIM at HSFO
In 2004, the Heart and Stroke Foundation of Ontario
(HSFO) Board of Directors approved a new strategy for
making an impact in the fight against heart disease and
stroke. This strategy, which is in addition to its ongoing
commitment to research and health promotion, would
begin to invest in 'Areas of Investment in Mission' (AIMs)
as another way to achieve its mission impact.
One of the major components of the HBP AIM Strategy is
the Hypertension Management Initiative (HMI) (see Fig-
ure 1). The Hypertension Management Initiative focuses
on what is acknowledged to be a critical issue in high
blood pressure – improving the management of this
chronic health condition by primary care providers (doc-
tors, nurse practitioners, nurses and community pharma-
cists) and patients. Working with several key partners,
including the Ontario College of Family Physicians, the
Registered Nurses Association of Ontario, and the Ontario
Pharmacists' Association, the HMI implements and evalu-
ates a local systems change educational approach
designed to enhance physician, nursing and pharmacist
approaches to high blood pressure detection, interven-
tion, and follow up measures. In addition, it is intended
to improve communication and collaboration between
these healthcare providers thus positively impacting
patient self management.
The pilot (alpha) phase, "Primary Care Partnerships for
Blood Pressure Reduction", was funded by the Ministry of
Health and Long-Term Care, in the Province of Ontario,
through the Primary Healthcare Transition Fund (PHCTF)
and was completed in July 2006. The alpha phase evalua-
tion revealed a statistically significant increase in screen-
ing (BP was measured at 45.7% of visits vs. 27.8% pre-
program) and diagnosis of hypertension (11% vs. 4.8%
pre-program) as well as a trend towards improved follow
up and better control (31% of non-diabetic patients con-
trolled vs. 25% pre-program, 58% of diabetic patients
controlled vs. 46% pre-program). However the sample
size was small at approximately 296 patients. The secondBMC Health Services Research 2008, 8:251 http://www.biomedcentral.com/1472-6963/8/251
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phase, termed, the 'HMI Beta Phase', is fully funded by
HSFO. The trial will be managed by the Heart and Stroke
Foundation of Ontario using a team of experts. To date,
eleven provider sites have been recruited across the prov-
ince.
Key Objectives of HMI – Beta Phase
The HMI Beta Phase is designed to improve patient out-
comes with respect to the control of blood pressure. There
are two key elements to the initiative. Firstly, it is designed
to improve provider practices and management of essen-
tial hypertension. Secondly, it is designed to improve pro-
vider-patient interactions and patient self-management of
hypertension.
The HMI Beta Phase will achieve these objectives by incor-
porating various strategies, including inter-professional
education, practice outreach and facilitation, an inter-pro-
fessional healthcare provider toolkit and a patient toolkit
(see Table 1). Together, these tools and interventions are
intended to enhance collaboration amongst primary
healthcare professionals (physicians, nurses, nurse practi-
tioners and community pharmacists) and between health-
care professionals and patients to enhance patient self
management of blood pressure and improve the manage-
ment and control of hypertension. The HMI beta phase
also aims to determine and measure the effectiveness of
the tools and improve best practice use of the current
Canadian Hypertension Education Program (CHEP) rec-
ommendations [5] with a larger sample size of healthcare
providers and patients than in the HMI Alpha phase. The
HMI beta phase aims to measure the effectiveness of this
initiative on a larger sample size by roughly quintupling
the number of healthcare providers and patients.
The HMI Beta phase is a three-year initiative, which will
end in 2010 to determine the effectiveness of the toolkits
High Blood Pressure Strategy Figure 1
High Blood Pressure Strategy.
Table 1: Aspects of the HMI beta phase
• interactive, inter-professional education workshops, reflective exercises
• practice outreach and support to healthcare providers to support and assist in the integration of the tools and interventions in their practices
• inter-professional, evidence-informed healthcare provider toolkit that incorporates clinical reminders and prompts and practice audit feedback 
and aids inter-professional communication
• evidence-informed, leading edge patient toolkit that provides information and education and supports patient self-management.BMC Health Services Research 2008, 8:251 http://www.biomedcentral.com/1472-6963/8/251
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and interventions on the management and control of
hypertension.
Methods and design
Overview of the Evaluation Methodology
Evaluation Design
To evaluate this initiative, a prospective delayed interven-
tion design has been selected. See Table 2 for key evalua-
tion indicators. Although all sites ultimately will receive
the intervention, six of the sites will be assigned to receive
the intervention immediately (these sites will be referred
to as "immediate intervention group"), while the remain-
ing five sites will receive the intervention after several
months, but will serve as a comparison during this delay
period (these sites will be referred to as "delayed interven-
tion group"). Further details regarding assignment to the
immediate and delayed intervention groups will be dis-
cussed in a later section.
Rationale for the Evaluation Design
The reasoning for this delayed approach is that it helps to
minimize the potential for threats to internal validity,
which are defined as alternate explanations for outcome
results other than the impact of the intervention itself. The
inclusion of the delayed group controls for outside influ-
ences that may occur over time such as educational mate-
rials, new research results relating to hypertension or the
release of new clinical practice recommendations.
As shown in the timeline (Table 3), the immediate inter-
vention sites will receive the intervention over a 9 month
period between Time 2 and 3, including the workshop
and all tools developed, whereas the delayed intervention
sites will not begin receiving the intervention until Time
3. Thus, between Time 2 and Time 3, it is hypothesized
that healthcare providers in the immediate intervention
sites will begin to use the tools developed by HSFO and to
optimize their management of hypertensive patients.
Healthcare providers in the delayed intervention sites will
not have received the intervention and are expected to
continue with treatment as usual. It is planned that blood
pressure measurements will be conducted at Time 3 for
patients in both the immediate intervention (after 9
months of the intervention) and delayed intervention (at
their baseline) sites. Since the patients in the immediate
intervention sites will have been enrolled nine months
earlier, it is expected that their blood pressures in follow
up visits will be better controlled (due to improvements in
provider hypertension management practices stemming
from their participation in the initiative and usage of tools
developed) than those of their counterparts in the delayed
intervention sites who will be providing their baseline BP
reading at Time 3 when they are prepared to start the inter-
vention.
HMI Beta Phase Action Pathway
In-Depth Initiative Components
Inter-professional Collaboration: Coach Selection and Training
In order to facilitate inter-professional collaboration,
which is an integral part of this initiative; coaches from
each of the three professions (Physicians, Nurses/Nurse
Practitioners, and Pharmacists) at each of the sites were
Table 2: Key Evaluation Indicators of Interest
Sustainability of the Hypertension Management Initiative program
 Development and usage of information management systems to improve and standardize high blood pressure patient care and treatment and 
to improve outcomes
 Statement of intention by participating healthcare providers to continue using key tools and learnings from the Hypertension Management 
Initiative.
Improved hypertension management practices by healthcare providers participating in the Hypertension Management Initiative
 Improved knowledge regarding best practices in management of patients with high blood pressure/hypertension
 Improved consistency with current CHEP recommendations in time elapsed from first high blood pressure reading to hypertension diagnosis
 Improved healthcare provider medication prescribing for hypertension patients consistent with current CHEP recommendations
 Improved assessment of medication adherence and side effects in high blood pressure/hypertension patient visits
 Improved assessment of global cardiovascular disease risk in patients with high blood pressure/hypertension
 Improved assessment of high blood pressure/hypertension patients' lifestyle risk factors and readiness to undertake lifestyle modifications
 Improved provision of support and advice to motivate high blood pressure/hypertension patients to make lifestyle recommendations
 Improved follow-up of high blood pressure/hypertension patients consistent with current CHEP recommendations
 Improved quantity and quality of inter-professional collaboration in management of patients with high blood pressure/hypertension.
Improved control of blood pressure among patients reached
 Reduced blood pressure readings of hypertension patients
 Increased proportion of patients with hypertension with blood pressure controlled to target
 Improved adherence of hypertension patients to prescribed hypertension medication(s)
 Improved adherence of high blood pressure/hypertension patients to their selected lifestyle changesBMC Health Services Research 2008, 8:251 http://www.biomedcentral.com/1472-6963/8/251
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identified to function as enablers and to provide a link
between the enrolled sites and the HSFO. The coaches
were identified at each of the sites and invited to attend an
orientation session for this role. During the course of the
HMI, regular communication with the participating
healthcare providers will be maintained including peri-
odic meetings of practitioners will continue for the three
years of the project.
Site Selection and Provider Recruitment
A total of 11 primary care practice sites have been
recruited for the HMI Beta Phase. At these sites, there are
a total of 49 family physicians and 15 nurse practitioners,
each of whom is asked to recruit 100 to 200 patients per
full time equivalent rostering physician/nurse practi-
tioner, a potential for up to 8,000 patients. Criteria for site
recruitment are found in Table 4.
Community pharmacists were recruited based on a con-
venience sample of the community pharmacies neighbor-
ing each of the participating medical clinics. To date there
have been more than 150 pharmacists recruited. The final
breakdown of potential participating healthcare providers
by site is provided in Table 5. Each healthcare provider
will have access to a variety of tools and resources to assist
in improving management of hypertensive patients. There
are no risks anticipated from a healthcare providers' par-
ticipation in this study.
A series of tools were developed and piloted in the in the
alpha phase of this initiative. These include specific tools
for physicians, nurse practitioners and pharmacists as well
as tools for patients. Descriptions of these tools are given
in Table 6.
The patient will also be offered the patient toolkit, includ-
ing the "Take the Pressure Off" education/resource book.
This patient resource provides information and education
on hypertension, its risk factors, lifestyle change informa-
tion, and lists other resources. The Patient-Provider Agree-
ment is incorporated into the "Take the Pressure Off"
book and is to be reviewed and completed during the ini-
tial enrolment visit, including the BP goal, the patient's
selected lifestyle risk factor which (s)he wishes to focus on
in the coming months/years and the patient's personal
plan of action for this selected lifestyle risk factor. Docu-
mentation of the BP goal and patient selected lifestyle risk
factor in the HBP Flow sheet is also done.
Prescriptions are written using an 'Rx Dx' prescription
(seen in figure 2), in which any diagnoses of hyperten-
sion, dyslipidemia or diabetes can be identified at the bot-
tom of the prescription. This enables the communication
of these diagnoses to the patient's pharmacist, who can
then support and reinforce the key messages and offer fur-
ther lifestyle and medications counselling to the patient.
A patient counselling tool, the "Reach Your Goal of BP
Table 3: HMI Beta Phase Evaluation Timeline
T i m e  1T i m e  2T i m e  3T i m e  4T i m e  5
Immediate 
Intervention
Measurement:
• BP readings 
(sphygmom.)
• site characteristics
• practice patterns re. 
HTN management
Receive intervention:
• workshop
• tools enrolment of 
patients
Measurement:
• baseline BP readings 
(BpTRU)
(continue to receive 
site support for 
intervention)
Measurement:
• follow up visit
• BP readings 
(BpTRU)
(continue to receive 
site support for 
intervention)
Measurement:
• follow up visit
• BP readings 
(BpTRU)
Measurement:
• follow up visit
• BP readings 
(BpTRU)
• practice patterns re.
HTN management
Delayed 
Intervention
Measurement:
• BP readings 
(sphygmom.)
• site characteristics
• practice patterns re. 
HTN management
treatment as usual receive intervention:
• workshop
• tools
enrolment of patients
measurement:
• baseline BP readings 
(BpTRU)
(continue to receive 
site support for 
intervention)
Measurement:
• follow up visit
• BP readings 
(BpTRU)
Measurement:
• follow up visit
• BP readings 
(BpTRU)
• practice patterns re. 
HTN management
Table 4: Criteria for site recruitment
• Organized primary healthcare team configuration (e.g. Family Health Teams, Family Health Networks, Community Health Centers) that have a 
capitated or salaried fee structure. (for definition of these types primary care practice groups, see footnote)
• Geographic vicinity to reflect Ontario's diverse needs (northern, urban, and rural).
• Minimize cross research bias. Each primary healthcare team selected will not be participating in any other hypertension studiesBMC Health Services Research 2008, 8:251 http://www.biomedcentral.com/1472-6963/8/251
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Control" fact sheet, is provided to the pharmacist, for use
in patient counselling.
An office automated blood pressure monitor, the BpTRU,
is provided to each family physician and nurse practi-
tioner. The BpTRU monitor is to be used to take the blood
pressure reading [6]. As data from each healthcare pro-
vider (physicians and nurse practitioners) is inputted in
the web based data set, confidential practice audit reports
will be produced for each healthcare provider. The HMI's
supporting practice and behavior change tools that are to
be integrated into practice will be presented during the
Launch Workshop.
Assignment to Immediate Intervention and Delayed intervention 
groups
Assignment to the immediate intervention and delayed
intervention groups will be conducted at the site level
rather than at the practitioner level or patient level. This is
to mitigate the potential risk at a site of "contamination"
of the comparison by practitioners sharing tools and
information about hypertension management (as well as
patients), if some practitioners at a site were assigned to
the immediate intervention group and some to the
delayed intervention group.
Initial consideration was given to randomizing the
groups, however with only 11 sites, randomization posed
risks of introducing bias. Sites in neighbouring communi-
ties could have cross contamination; the diverse and vast
geography of the Province of Ontario must be accounted
for, particularly because of the more rural north and the
more densely populated south. Also, approximately half
of the clinics had adopted an electronic medical record at
study start, indicating the potential for the more rapid
adoption of new techniques. With only 11 sites and too
many variables to stratify by to allow randomization, in
order to ensure that the sites in the immediate interven-
tion and delayed intervention groups are not different
from each other, the sites will be assigned to the interven-
tion groups manually to ensure a distribution of the vari-
ables as evenly as possible. Allocation of sites into
immediate intervention and delayed intervention groups
will also take into consideration geographic proximity
between sites. Sites in neighbouring communities will be
allocated to the same grouping since communication
between participants in proximal groupings could poten-
tially contaminate comparisons.
Demographic and baseline data will be compared
between the immediate intervention and delayed inter-
vention groups to determine if the groups did differ signif-
Table 5: Recruited HMI Beta Phase Sites
Pilot Site Community
(listed by number)
Type of
Primary Care Site
Medical
Record Type
# Physicians
+ NP
# NP # Nurses
(RN and RPN)
# Pharmacists
1F H T P a p e r 1 6 1 0 2 1
2F H T E M R 1 2 2 6
3 FHT EMR 5 1 3 25
4F H T E M R 1 0 0 1
5C H C P a p e r 1 4 3 1 2
6 FHT EMR 3 1 2 13
7 FHT EMR 9 1 2 20
8F H T P a p e r 2 1 1 4
9F H T P a p e r 1 2 1 1 6
10 FHT Paper 10 1 6 7
11 FHT EMR 5 2 4 7
Total 63 17 25 132
FHT = Family Health Team, CHC = Community Health CentersBMC Health Services Research 2008, 8:251 http://www.biomedcentral.com/1472-6963/8/251
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Table 6: HMI Healthcare Provider and Patient Toolkits
Toolkit Tool Name Description Target Audience
Provider Toolkit 1. Rx Dx Pads 
(with Diagnosis check off)
Communication tool for physicians to provide 
pharmacists
diagnosis information with prescription allowing 
pharmacist to counsel patient appropriately and 
reinforce physician's messages regarding treatment 
adherence. It will be available in both paper and 
electronic form according to site preference.
Physician/Nurse Practitioner
2. Proper Methods to
Take Blood Pressure
A summary of directions for providers and patients 
on how to take blood pressure; includes step by 
step instructions for patients before and during BP 
measurements to ensure a correct BP reading.
3. Bp TRu 300 Automated office blood pressure measurement 
devices.
4. Blood Pressure Pocket Guide An easy to use reference, pocket guide with Blood 
Pressure Risk chart/BMI calculator, waist 
circumference risk and stages of Change and 
counselling information to help your patients with 
their identified lifestyle modification. Patients also 
like the visual risk mapping format of the charts.
Provider
5. HBP Flow Sheet & Assessment 
Form
Charting tool to record patient's progress with 
HBP care plan over time. This tool will remain in 
the patient's chart and will be used in paper version 
only in paper based sites. That form will be also 
faxed to an optical recognition site that will digitize 
the data and send it to a secure web-based custom 
data set. EMR (electronic medical record) sites will 
be sending the data directly to the same secure 
web based custom data set through a secure link.
Provider
6. Confidential Provider
Practice Audit Reports
Regular confidential practice reports are generated 
from the web-based data set and provided to the 
healthcare providers, namely physicians and nurse 
practitioners. The reports provide confidential, 
anonymous comparisons of one's practice to other 
participating healthcare providers and sites.
The dataset is hosted on a PHIPA compliant server.
Physician/Nurse Practitioner
7. RNAO-HSFO Nursing Best 
Practice Guideline, Nursing
Management of Hypertension
A nursing best practice guideline collaboratively 
developed by the Registered Nurses' Association 
of Ontario and the Heart and Stroke Foundation of 
Ontario, with funding support from the Ontario 
Ministry of Health and Long-Term Care. This 
guideline has been endorsed by CHEP.
Nurses, Nurse Practitioners
8. CHEP Recommendations Canadian Recommendations for the Management 
of Hypertension, published yearly by the Canadian 
Hypertension Education Program(CHEP)
9. 'Reach Your Goal in Your 
Blood Pressure Control'
Fact Sheet
The Reach Your Goal fact sheet is intended as an 
aid to assist in the lifestyle counselling of 
hypertensive patients.
Patient Lifestyle changes and the effect on Blood 
pressure are listed on the first side. The other side 
has Blood Pressure Basics: one page patient 
education piece on blood pressure that outlines 
definitions and management. No major changes to 
the previously ethically approved
version except updating information based on the 
new CHEP guidelines.
PharmacistsBMC Health Services Research 2008, 8:251 http://www.biomedcentral.com/1472-6963/8/251
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icantly in terms of healthcare provider practice patterns,
site characteristics, and patient blood pressure control
before the implementation of the program. If any statisti-
cally significant differences are detected between immedi-
ate intervention and delayed intervention groups, then
these will be taken into account in analyses following the
immediate intervention. The immediate intervention
group will have the intervention for a longer duration
than the delayed intervention group, providing an oppor-
tunity to determine whether there is a "dosage effect"
associated with having the immediate intervention for a
longer time period.
Statistical Design and Analysis
The standard deviation used to calculate sample size is
derived from results of the alpha phase. In order to have
power of 0.9 to detect a difference of 5 mmHg with beta =
0.20 and alpha = 0.05, 337 patients would be required in
each group.
Descriptive statistics will be calculated for all variables of
interest. Continuous measures will be summarized using
means and standard deviations whereas categorical meas-
ures were summarized using counts and percentages. For
univariate analyses, two sample two-sided t tests will be
using for continuous data, whereas chi-square analyses
(or Fisher's exact tests in the case of cell sizes) will be used
for categorical data. Regression analyses will be con-
structed from covariates known to impact on blood pres-
sure. All analyses will be carried out using SAS Version 9.1
(SAS Institute, Cary, NC, USA).
Patient Recruitment Strategy and Consent
Shortly before attending the Launch Workshop, the
healthcare providers will identify potential eligible
patients for the HMI Beta Phase, based on identified inclu-
sion and exclusion criteria. Each full time equivalent ros-
tering physician and nurse practitioner is requested to
recruit a minimum of 100 patients and up to a maximum
of 200 patients. A patient friendly consent form has been
developed and will be signed by each participant. Copies
of the consent, an accompanying script and other materi-
als will be provided to each participating office. In addi-
tion to these documents, an implementation guide will
also be provided to each site. (Thorough explanations of
the materials will also be provided by Heart and Stroke
Outreach and Practice Support Specialists at 'on site' vis-
its.)
Patient Toolkit 1."Take the Pressure
Off' Resource Book
Evidence-informed patient HBP education 
workbook will be provided to all patients. It will 
serve as a knowledge resource utilizing easy 
language. This resource will also serve as an 
identification tool for the pharmacist to initiate 
lifestyle counselling with the enrolled and 
consented patients. It is consistent with the latest 
CHEP recommendations. There are 3 key 
components of this patient resource book:
i) An easy to read resource book designed to 
provide your patients with a basic understanding of 
high blood pressure and to promote self-
management
ii) Patient-Provider Agreement: A tool intended to 
promote conversations and concordance between 
patients and you, as well as patient's decision-
making.
iii) iii) Patient Log Book: An interactive tool that 
promotes self-management among patients. It 
enables monitoring of their progress for 3 key co-
morbidities: hypertension; diabetes; dyslipidemia, 
and tracking of medications and questions/topics 
they wish to follow-up with different members of 
the healthcare team.
Patient
4. Blood Pressure Action Plan 
http://www.heartandstroke.ca
HSFO online or phone-in service that asks an 
individual questions regarding lifestyle and risk 
factors and offers a personalized plan with realistic 
strategies for living a healthier life. Individuals may 
also opt into an email support program that sends 
periodic email messages to help the individual 
through the stages of change. Previously ethically 
approved and no changes has been introduced.
General public patients who enter 
the Initiative will be referred to 
BPAP.
Table 6: HMI Healthcare Provider and Patient Toolkits (Continued)BMC Health Services Research 2008, 8:251 http://www.biomedcentral.com/1472-6963/8/251
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Appointments with the potential eligible patients will be
scheduled to occur subsequent to the workshop with the
participating practitioners. During this visit, these poten-
tial eligible patients will be provided with information
about the HMI Beta Phase, patient consent will be
requested and documented and a baseline assessment
including physical measures conducted and documented.
When a patient provides consent, (s)he is deemed to have
enrolled in the HMI Beta Phase. Ethics approval has been
obtained from the Sunnybrook Health Sciences Centre
Research Ethics Board (approval #: 474-2006).
Utilizing adult learning best practices, the format of the
site initiation Launch Workshop is one in which physi-
cians, pharmacists and nurses will learn together and dis-
cuss barriers and solutions to better manage hypertension
together and via small group breakout sessions, develop a
community practice plan to improve the management
and control of hypertension among their patients. The
purposes of this interactive, inter-professional workshop
include addressing any knowledge gaps identified in the
healthcare provider needs assessment, introducing con-
cepts of systems change theory and related applications,
and developing approaches to high blood pressure based
on inter-professional teamwork. This will be accom-
plished by providing information/education on best prac-
tices in management of hypertension, and a tool kit of
supporting practice and behaviour change tools to all par-
ticipating healthcare providers.
Implementation of Toolkit and Interventions
When a patient provides consent, (s)he is deemed to have
enrolled in the HMI Beta Phase. Only then will his/her
baseline data collected on the registration (baseline) visit
data form designed as a flow sheet, be entered into the
web-based dataset, using a unique ID to ensure that the
web-based dataset is anonymized and pseudonymized. A
flow sheet form will continue to be used during the sub-
sequent patient visits. The flow sheets will become a part
of the patient's chart. At the time of use, the flow sheet will
graphically show the trends from all earlier visits in several
key variables including systolic/diastolic blood pressure,
BMI/waist circumference, lipids and lifestyle goal varia-
bles.
At the time of recruitment, the sites in this initiative were
divided almost 50-50 in the use of either paper or elec-
tronic medical record (EMR) for clinical/patient record
documentation. Existing EMR systems at the sites are una-
ble to systematically and fully capture and subsequently
extract and upload the patient data required for this
project. Therefore, each participating EMR vendor has
undertaken to create and insert into their system a "data
collection template screen" specifically customized to cap-
ture and export the data set requirements of this project.
After a patient has consented, a copy of the patient infor-
mation needed for this strategy is exported from the prac-
titioner's EMR and transferred securely into the project's
central, securely housed clinical data repository ("web-
based dataset"). Specifically, the data will be formatted in
a standardized project-specific format as an XML file,
along with enforcement of XSD-based validity checks, and
transmitted to the web-based data set via HTTPS
(encrypted HTTP) using a SOAP-based web service pro-
vided by the database host. The aforementioned encryp-
tion will prevent access to patient information while it is
in transit. For electronic medical record (EMR) sites, the
data will automatically be exported once nightly in a
standardized format from the site's EMR to the web-based
dataset.
For paper-based sites, the initial paper flow sheet is pro-
vided to each healthcare provider with a paper based clin-
ical record documentation system. Follow up visit paper
flow sheets are obtained by downloading the follow-up
visit form from the website shortly before every follow-up
visit, i.e. after the prior visit's data have been processed
and incorporated into the updated data graphs. Two
Rx Dx Prescription Figure 2
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methods are available for transferring the data from the
paper forms to the web-based data set. In the first method,
at the end of each visit, the flow sheet will be faxed by toll-
free number to the data centre for optical scanning and
aggregation into the web-based data set. To insure data
accuracy, the scanned information will be validated by a
human operator at the centre and corrected for errors. The
faxed form will include neither the name of the patient
nor any other identifying information such as address or
phone number. This is possible because each patient will
be assigned a unique sequential identifier by the practi-
tioner's office at the time of the baseline (registration)
visit, the identifier being pre-printed on the practitioner's
pad of blank Registration visit forms. The practitioner's
office will subsequently supply the patient's name directly
into the web-based dataset by matching with the anony-
mous identifier and birthdate. This procedure facilitates
the subsequent downloading of each patient's own fol-
low-up forms containing their pre-printed data graphs,
whose ongoing feedback is an important component to
promoting the success of the project. In the second
method, at the end of each visit, the data from the flow
sheet will be manually entered into a secure website
directly linked to the web-based data set.
After patient information is entered into the dataset,
monthly and quarterly confidential practice audit reports
will be available to all practitioners on the secure website
linked to the web-based dataset. Moreover, the practi-
tioner will be able to access the data set at anytime and
generate ad hoc "drill-down" reports on his/her patients
only. While the same practitioner can compare aggregate
data from different sites, he/she cannot access the individ-
ual patient information of another physician. The web-
based dataset will generate regular confidential practice
reports based on the data submitted, for each participat-
ing physician and nurse practitioner, comparing the prac-
tice to that of other providers at the same site and to those
of the other sites and participating healthcare providers.
Reports are also generated at a site level for the other
healthcare providers to access.
The web-based dataset will be hosted on a Personal
Health Information Protection Act (PHIPA) compliant
server provided by the dataset developer.
The patient will also be offered the patient toolkit, includ-
ing the "Take the Pressure Off" patient book. This patient
resource provides information and education on hyper-
tension, its risk factors, lifestyle change information, and
lists other resources. The Patient-Provider Agreement will
be reviewed and completed, including the BP goal, the
patient's selected lifestyle risk factor which (s)he wishes to
focus on in the coming months/years and the patient's
personal plan of action for this selected lifestyle risk fac-
tor. The Patient-Provider Agreement is incorporated into
the "Take The Pressure Off". The BP goal and patient
selected lifestyle risk factor is also documented in the HBP
Registration (baseline) and Flow sheet (follow-up) data
forms.
In order to assess the impact of the Hypertension Manage-
ment Initiative on both healthcare provider practice pat-
terns and patient blood pressure readings and control, it
is necessary to compare data from the pre-program period
to the program period. In order to assess any changes from
before to after the intervention, a combination of chart
reviews, for the pre-program period, and the web-based
patient dataset, for the program period, will be used. Thus,
data about the practice patterns of individual healthcare
providers and their individual patients' blood pressure
data will be used as their own comparators pre-interven-
tion versus post-intervention.
Given that HSFO approached this particular group of
health care providers to participate in a program relating
to hypertension, this may have heightened their aware-
ness of the issue and affected their management of
patients with hypertension (in addition to the influence
of the intervention itself). This phenomenon in which
subjects of research may be affected by the knowledge that
they are subjects of research is known as the Hawthorne
Effect. For this reason, data will be collected from both the
immediate intervention and delayed intervention groups
pertaining to office visits conducted during the six months
prior to initial contact with sites for recruitment into the
initiative as well as data from office visits after first contact
but before the site initiation workshop. Gathering this
data will allow an assessment of practice patterns for these
groups between the pre-recruitment period and the period
following recruitment, which may relate to the Haw-
thorne Effect. As well, this will allow comparisons to be
made between the immediate intervention and delayed
intervention groups in terms of patient blood pressure
readings as well as healthcare provider practice patterns.
In the patient consent form, patients are informed that
information from their medical chart may be collected in
order to evaluate the education and tools provided to
themselves and their health care provider, and that all
information collected would be kept strictly confidential
and would be grouped for analysis. All participating and
nurse practitioners have provided written consent to a
chart review with the intent to evaluate the education and
tools provided to the healthcare providers.
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